What’s New with GlobalData's Pharmaceuticals and Healthcare Reports

25 Aug 2011 • by Natalie Aster

Market Publishers Ltd informs that new GlobalData's Pharmaceuticals and Healthcare Reports have been added to its catalogue:

Trigeminal Neuralgia (TN) Therapeutics - Pipeline Assessment and Market Forecasts to 2017. GlobalData estimated the trigeminal neuralgia (TN) therapeutics market to be worth $83.53m in 2010 and forecasts it to grow at a Compound annual growth rate (CAGR) of 2.7% to reach $100.62m in 2017. The low growth is because TN therapeutics market is dominated by generics. The lower cost of generics brings down the overall market value. The TN therapeutics pipeline does not have any industry sponsored molecules in clinical development.

Peripheral Ulcerative Keratitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017. GlobalData valued the global Peripheral Ulcerative Keratitis (PUK) therapeutics market at $418m in 2010 and forecast it to grow at a Compound Annual Growth Rate (CAGR) of 7.4% to reach $690m by 2017. This growth is primarily attributed to the expected increase in the general population. The increased use of contact lenses will also lead to a marginal increase in infectious PUK.

Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017. GlobalData estimates that the global Post - traumatic Stress Disorder (PTSD) therapeutics market was valued at $2.2 billion in 2010, and it is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.2% over the next seven years, to reach $2.9 billion by 2017. This slow growth is primarily attributed to low disease awareness and usage of generic drugs. The current competitive landscape consists of branded, generic and off - label drugs.

Ewing’s Sarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017. GlobalData estimates that the global Ewing’s sarcoma therapeutics market was valued at $7.4m in 2010, and is forecast to grow at a slow pace with a compound annual growth rate (CAGR) of 3.4% over the next seven years to reach $9.4m by 2017. This slow growth is primarily attributed to the slow increase in the patient population and late diagnosis of the disease.

Published: July’11  

Per Report Price: $2,000 (Single User License)

More new market research reports by GlobalData can be found at https://marketpublishers.com/members/global_data/info.html

To order the report or ask for sample pages contact ps@marketpublishers.com

 

Contacts

MarketPublishers, Ltd.

Tanya Rezler

Tel: +44 208 144 6009

Fax: +44 207 900 3970

ps@marketpublishers.com

www.marketpublishers.com